Therapeutic agent containing pyrazolo[3,4-d]pyrimidine compound as active ingredient

Number of patents in Portfolio can not be more than 2000

United States of America

PATENT NO 12186320
APP PUB NO 20210252000A1
SERIAL NO

17271125

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Provided is an anti-tumor agent for the treatment of a HER2-positive tumor that is tolerant to other anti-tumor agents or an intractable HER2-positive tumor. More specifically provided is a therapeutic agent for a HER2-positive tumor that is tolerant to other anti-tumor agents or an intractable HER2-positive tumor, which contains a pyrazolo[3,4-d]pyrimidine compound or a salt thereof as an active ingredient.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
TAIHO PHARMACEUTICAL CO LTDTOKYO JAPAN

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Fujioka, Yayoi Ibaraki, JP 2 0
Irie, Hiroki Ibaraki, JP 18 154

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Jul 7, 2028
7.5 Year Payment $3600.00 $1800.00 $900.00 Jul 7, 2032
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jul 7, 2036
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00